Trials / Conditions / Homologous Recombination Deficiency

Homologous Recombination Deficiency

19 registered clinical trials studyying Homologous Recombination Deficiency — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	The HER Project: HRD in EGFR-mutated NSCLC NCT07303218	IRCCS San Raffaele	—
Withdrawn	Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repai NCT06527690	Latin American Cooperative Oncology Group	Phase 2
Recruiting	EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors NCT06525298	Eisbach Bio GmbH	Phase 1 / Phase 2
Active Not Recruiting	Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors NCT06545942	MOMA Therapeutics	Phase 1
Recruiting	Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency NCT06095141	Fudan University	Phase 2 / Phase 3
Unknown	Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency NCT05461690	Zhejiang Cancer Hospital	Phase 2
Unknown	HRD and Resistance to PAPPi in EOC Patients NCT05310370	Lei Li	—
Recruiting	Olaparib in Patients With HRD Malignant Mesothelioma NCT04515836	University of Chicago	Phase 2
Unknown	A Training Set for the HRD Model in EOC NCT04651933	Lei Li	—
Completed	A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer NCT04651920	Lei Li	—
Unknown	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071	Xiaoxiang Chen	Phase 2
Recruiting	A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies NCT04503265	AtlasMedx, Incorporated	Phase 1 / Phase 2
Unknown	Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer NCT04190667	Lei Li	—
Completed	Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) NCT04174716	Idience Co., Ltd.	Phase 1 / Phase 2
Withdrawn	Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676	M.D. Anderson Cancer Center	Phase 2
Terminated	Functional Analysis of BRCAness NCT04780945	Leiden University Medical Center	Phase 2
Terminated	Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Pros NCT03442556	University of Washington	Phase 2
Recruiting	Bipolar Androgen Therapy + Carboplatin in mCRPC NCT03522064	St Vincent's Hospital, Sydney	Phase 2
Terminated	Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignanci NCT03209401	Georgetown University	Phase 1